Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A new study identifies microRNAs that are enriched in exosomes secreted from cardiosphere-derived cells and which are associated with cardiac repair in pigs and humans with dilated cardiomyopathy.
A new study identifies the mitochondrial protein ALDH4A1 as a potential biomarker of atherosclerosis and as a target antigen of protective autoantibody A12, which might have therapeutic potential.
In the AFFIRM-AHF trial, the use of intravenous ferric carboxymaltose in patients with acute heart failure and iron deficiency was associated with a reduction in hospitalization for heart failure and cardiovascular death.
In patients with recurrent pericarditis, treatment with rilonacept, an engineered fusion protein that acts as an IL-1 trap, leads to a rapid resolution of recurrent pericarditis episodes and reduces the risk of pericarditis recurrence.
Omecamtiv mecarbil (a myosin activator) and mavacamten (a myosin inhibitor) have beneficial effects in patients with heart failure with reduced ejection fraction or obstructive hypertrophic cardiomyopathy, respectively.
Findings from two clinical trials indicate that cryoablation as first-line treatment is superior to drug therapy for the prevention of atrial arrhythmia recurrence in patients with paroxysmal atrial fibrillation.
In the TIPS-3 trial, a single polypill comprising blood-pressure-lowering and cholesterol-lowering drugs, together with a daily dose of aspirin, reduced cardiovascular events in people at risk of cardiovascular disease.
Sotagliflozin reduces the risk of adverse cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease or worsening heart failure according to the SCORED and SOLOIST-WHF trials.
In patients with heart failure who are carriers of a clonal haematopoiesis driver mutation in DNMT3A, circulating monocytes have a pro-inflammatory transcriptome, which might worsen disease progression.
A new study identifies a previously unknown paracrine signalling system in the human atrium that is mediated by calcitonin produced by atrial cardiomyocytes and is involved in controlling atrial fibrogenesis and arrhythmia.
Extreme heat events are now more frequent in many parts of the world as a result of climate change. The combined effects of heat, air pollution, individual age, and socioeconomic and health status are responsible for avoidable acute events of cardiovascular disease and need to be considered in order to prevent and treat cardiovascular diseases effectively.
A metabolomics approach to assess heart energy metabolism in humans provides new insights into what fuels are used by both the failing and non-failing heart.
In this Comment, Nikki Gillum Posnack discusses how the increasing use of plastics in everyday life has potentially harmful effects on cardiovascular health.
After myocardial infarction in mice, cardiac macrophages produce matrix metalloproteinase 14, which promotes endothelial-to-mesenchymal transition, cardiac fibrosis and myocardial dysfunction.